Tech Company Financing Transactions
Shinobi Therapeutics Funding Round
On 12/12/2023, Shinobi Therapeutics secured $51 million in Series A funding from Eight Roads, EQT Life Sciences and F-Prime Capital.
Transaction Overview
Company Name
Announced On
12/12/2023
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its 'Katana' iPS-T cell therapy platform and progress its first program to treat GPC3+ solid tumor cancers toward the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA Undisclosed
USA
San Francisco, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs. Shinobi uses the world's most comprehensive immune evasion technology to unlock the full potential of iPSCs. This is Shinobi, the first iPS cell therapy compatible with the patient's immune system. Shinobi's comprehensive immune evasion technology not only shields against T-cells and innate immunity, but also against antibody-mediated rejection.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Kemp
Co-Founder
Tobias Deuse
Co-Founder
Shin Kaneko
Browse more venture capital transactions:
Prev: 12/12/2023: Geo-Solutions venture capital transaction
Next: 12/12/2023: NeoCarbon venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs